Melanotan II Protocol

Evidence Level: Investigational / Theoretical

Primarily preclinical or very limited human data — mechanism-based reasoning more than a demonstrated clinical effect. Treat as investigational.

Human evidence: Primarily self-reported use data and FDA/poison-control adverse-event reports rather than controlled clinical trials.

Animal evidence: Rodent melanocortin-receptor pharmacology studies.

Introduction & Mechanism of Action

Broader melanocortin-receptor agonist studied for pigmentation and libido-related research.

Non-selective melanocortin-receptor agonist engaging MC1R (pigmentation), MC3R and MC4R (linked to appetite and libido effects) — its broader receptor profile versus Melanotan I is both the source of its libido-research interest and its wider side-effect range.

Receptors/targets: Melanocortin-1 receptor (MC1R), Melanocortin-3 receptor (MC3R), Melanocortin-4 receptor (MC4R)

Areas of Research Interest

• Pigmentation research
• Libido-related studies

Benefits Reported in Research

• Pigmentation research
• Libido-related studies

Reported Research Dosing Range

The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.

Reported range: 0.25–1 mg

Reported frequency: 1× daily, subcutaneous

Reported cycle duration: 4–8 weeks

Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.

Research Reference Data

Published research on Melanotan II reports administration at 0.25–1 mg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.

Reconstitution Reference

Published research protocols reconstitute a 10 mg vial with 2 mL bacteriostatic water, yielding a concentration of 5.00 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.

Research Protocol Timeline

A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.

Dilution Guide

Reconstitute with 2 mL bacteriostatic water

Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.

Handling Guide

General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.

Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.

Storage

Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.

Monitoring

Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.

Side Effects

• Nausea
• Flushing
• Spontaneous erections (reported, related to the melanocortin/libido mechanism)
• Uneven skin darkening
• Appetite suppression

Contraindications

• History of melanoma or atypical nevi
• Cardiovascular disease (theoretical concern given reported blood-pressure effects)
• Pregnancy

Drug interactions

• Not well characterized in controlled human trials — most data is from adverse-event reporting rather than interaction studies

Safety

• Nausea, particularly during dose escalation
• Documented adverse-event reports in FDA and poison-control literature
• Purity and dosing highly variable in unregulated supply

FDA and poison-control literature document adverse-event reports; purity and dosing are highly variable in unregulated supply.

Expected Results & Comparison

Melanotan II is less receptor-selective than Melanotan I (which targets MC1R only), which is why it carries libido-related research interest but also a wider adverse-event profile. PT-141 (bremelanotide) is a related melanocortin agonist studied specifically for sexual-arousal disorders with an actual FDA-approved formulation for one indication — a stronger evidence base than Melanotan II for that specific use.

References

Continue